Welcome to our dedicated page for Nanovibronix SEC filings (Ticker: NAOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENvue Medical Inc. filings document the public-company transition from NanoVibronix Inc. and NAOV to the ENvue Medical name and FEED trading symbol, along with capital-structure and governance disclosures. Recent Form 8-K reports cover the completed certificate amendment for the name change, amendments to Series H Convertible Preferred Stock rights, material definitive agreements and security-holder rights.
The filing record also includes proxy materials for annual meeting matters, board and committee changes, registered direct offering documents involving common stock and prefunded warrants, and a late-filing notification for a quarterly report. These documents frame the company’s disclosure record around medical-technology operations, equity financing, preferred-stock terms, Nasdaq-listed common stock, corporate governance and periodic reporting obligations.
Bank of America and affiliates filed an amended Form 3/A for ENvue Medical, Inc., updating the reported event date to January 30, 2026 and confirming 10% owner status. The filing reports indirect beneficial ownership of 234,056 shares of common stock through subsidiaries BANA and BOFAS.
The disclosure relies on 1,088,192 outstanding shares as of December 5, 2025, as stated in a December 18, 2025 prospectus, which covers the resale of up to 7,962,279 shares of common stock and notes that additional issuances could materially increase outstanding shares and substantially dilute existing stockholders.
Bank of America and affiliates filed an amended Form 3/A for ENvue Medical, Inc., updating the reported event date to January 30, 2026 and confirming 10% owner status. The filing reports indirect beneficial ownership of 234,056 shares of common stock through subsidiaries BANA and BOFAS.
The disclosure relies on 1,088,192 outstanding shares as of December 5, 2025, as stated in a December 18, 2025 prospectus, which covers the resale of up to 7,962,279 shares of common stock and notes that additional issuances could materially increase outstanding shares and substantially dilute existing stockholders.
Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.
After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.
Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.
After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.
Bank of America Corp, Bank of America NA, and BofA Securities, Inc. jointly reported their initial beneficial ownership in Envue Medical, Inc. as 10% owners. The filing shows indirect ownership of 234,056 shares of common stock, held through Bank of America’s subsidiaries.
The 10% ownership status is based on 1,088,192 outstanding shares disclosed in Envue Medical’s Form 424B3 prospectus, which reports totals as of December 5, 2025. That prospectus covers the potential resale of up to 7,962,279 shares of common stock and notes that issuing additional shares could materially increase shares outstanding and substantially dilute existing stockholders.
Bank of America Corp, Bank of America NA, and BofA Securities, Inc. jointly reported their initial beneficial ownership in Envue Medical, Inc. as 10% owners. The filing shows indirect ownership of 234,056 shares of common stock, held through Bank of America’s subsidiaries.
The 10% ownership status is based on 1,088,192 outstanding shares disclosed in Envue Medical’s Form 424B3 prospectus, which reports totals as of December 5, 2025. That prospectus covers the potential resale of up to 7,962,279 shares of common stock and notes that issuing additional shares could materially increase shares outstanding and substantially dilute existing stockholders.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise $2,500,000 of the Additional Investment Right described in the July 18, 2025 Securities Purchase Agreement. The Certificate of Amendment was filed with the Delaware Secretary of State on January 30, 2026 and became effective upon filing, modifying the rights and preferences of the Series H preferred shares.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise $2,500,000 of the Additional Investment Right described in the July 18, 2025 Securities Purchase Agreement. The Certificate of Amendment was filed with the Delaware Secretary of State on January 30, 2026 and became effective upon filing, modifying the rights and preferences of the Series H preferred shares.
ENvue Medical, Inc. filed an initial insider ownership report for director Pellegrino Pionati as of 12/04/2025. The filing states in the explanation that no securities are beneficially owned, meaning the director reported holding no shares or derivative securities of the company at that time. This is a routine disclosure required for company insiders when they first become subject to reporting rules.
ENvue Medical, Inc. filed an initial statement of beneficial ownership for a director, indicating that as of the event date of 12/04/2025 the reporting person did not beneficially own any company securities. The filing is made by a single reporting person in their capacity as a director and confirms there are no non-derivative or derivative securities reported as owned.
ENvue Medical, Inc. is registering the resale of up to 7,962,279 shares of common stock for a selling stockholder. These include 2,377,533 shares issuable upon conversion of Series H Convertible Preferred Stock, 584,796 shares issuable upon exercise of related warrants, and up to 4,999,950 shares issuable as stock dividends on the Series H shares at a 9% annual rate. The company will not receive proceeds from any resale, but may receive cash if the warrants are exercised, which it plans to use for general corporate purposes. As of December 5, 2025, 1,088,192 common shares were outstanding, so full issuance of the registered shares would represent a very large increase in the share count and substantial dilution for existing holders. The filing also notes the company’s reverse stock splits, recent merger, name and ticker change to “FEED,” and ongoing Nasdaq listing compliance and auditor-related risks.
ENvue Medical, Inc., formerly known as NanoVibronix, Inc., has amended its certificate of incorporation to change its corporate name to ENvue Medical, Inc., effective December 12, 2025. On the same date, its common stock stopped trading on Nasdaq under the ticker symbol “NAOV” and began trading under the new symbol “FEED.”
The company states that the name change and ticker change do not affect the rights of its security holders and that its CUSIP remains the same. Under Delaware law, this amendment did not require stockholder approval. The company also issued a press release on December 12, 2025 to announce the name and symbol changes.
NanoVibronix, Inc. (NAOV) filed a current report announcing that it issued a shareholder letter on November 19, 2025. The letter was provided to investors as an exhibit to this report under a disclosure rule that covers company communications with the market, rather than as a formal financial or earnings filing. The report clarifies that this communication is being furnished, not filed, which means it is not automatically incorporated into other securities law filings or subject to certain legal liabilities.